Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Reck, 2021, Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%, J. Clin. Oncol., 39, 2339, 10.1200/JCO.21.00174 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer, N. Engl. J. Med., 378, 2078, 10.1056/NEJMoa1801005 Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865 Lamberti, 2020, Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, Crit. Rev. Oncol. Hematol., 156, 10.1016/j.critrevonc.2020.103119 Steuer, 2022, Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR -activating mutations, J. Clin. Oncol., 40, 9017, 10.1200/JCO.2022.40.16_suppl.9017 Spira A.I. IASLC | International association for the study of lung cancer. Accessed January 3, 2023. https://library.iaslc.org/search-speaker?search_speaker=87361. Rizzo, 2022, Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate, Br. J. Cancer, 127, 1381, 10.1038/s41416-022-01929-w Viscardi, 2022, Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis, Eur. J. Cancer Oxf. Engl. 1990, 177, 175 Saini, 2021, Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics, Expert Opin. Biol. Ther., 21, 945, 10.1080/14712598.2021.1936494 2023 AstraZeneca. A Phase 1b, multicenter, 2-part, open-label study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (Tropion-Lung04). clinicaltrials.gov; 2022. Accessed January 22, 2023. https://clinicaltrials.gov/ct2/show/NCT04612751. Tong, 2021, An insight into FDA approved antibody-drug conjugates for cancer therapy, Mol. Basel Switz, 26, 5847 Iwata, 2019, [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model. Najbauer J, ed, PLoS ONE, 14, 10.1371/journal.pone.0222280 Hotta, 2018, A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, 13, 273 Stinchcombe, 2017, Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC), J. Clin. Oncol., 35, 8509, 10.1200/JCO.2017.35.15_suppl.8509 Li, 2018, Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 36, 2532, 10.1200/JCO.2018.77.9777 NCCN Clinical Practice Guidelines in Oncology, Non-small cell lung cancer NCCN Evidence block. Published online March 16, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Li, 2022, Trastuzumab deruxtecan in HER2 -mutant non–small-cell lung cancer, N. Engl. J. Med., 386, 241, 10.1056/NEJMoa2112431 Li Bob T, Smit Egbert F, Goto Yasushi, et al. ESMO 2022- Phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer: updated analyses from DESTINY-lung01. Accessed January 3, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-congress?event_resources_filter_form%5Bsearch%5D=Bob%20T.%20Li. Smit, 2022, 975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): results from the DESTINY-Lung01 trial, Ann. Oncol., 33, S994, 10.1016/j.annonc.2022.07.1103 Goto, 2022, LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): interim results from the phase 2 DESTINY-Lung02 trial, Ann. Oncol., 33, S1422, 10.1016/j.annonc.2022.08.057 Pacheco, 2018, Antibody drug conjugates in thoracic malignancies, Lung Cancer Amst. Neth., 124, 260, 10.1016/j.lungcan.2018.07.001 Heist, 2017, Therapy of advanced non-small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 35, 2790, 10.1200/JCO.2016.72.1894 Garon E.B. IASLC | International association for the study of lung cancer. Accessed January 6, 2023. https://library.iaslc.org/virtual-library-search?product_id=24&author=&category=&date=&session_type=&session=&presentation=MA03.02&keyword=. Garon, 2021, MA03.02 TROPION-pantumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors, J. Thorac. Oncol., 16, S892, 10.1016/j.jtho.2021.08.118 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionabl... | OncologyPRO. Accessed January 13, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-of-datopotamab-deruxtecan-dato-dxd-in-patients-pts-with-advanced-metastatic-adv-met-non-small-cell-lung-cancer-nsclc-and-actionabl. PVI_slides_22ADC.pdf. Accessed January 13, 2023. https://c.peerview.com/live/programs/150207897-1/downloads/PVI_slides_22ADC.pdf?Promocode=&ProjectNumber=150207897_1. Camidge, 2021, Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 27, 5781, 10.1158/1078-0432.CCR-21-0765 Camidge, 2022, Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol., 40, 9016, 10.1200/JCO.2022.40.16_suppl.9016 Home - ClinicalTrials.gov. Accessed November 5, 2022. https://www.clinicaltrials.gov/ct2/home. Pa, 2022, Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer, Cancer Discov., 12 Gazzah, 2020, Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), J. Clin. Oncol., 38, 9505, 10.1200/JCO.2020.38.15_suppl.9505 Ricordel, 2022, Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), J. Clin. Oncol., 40, 9039, 10.1200/JCO.2022.40.16_suppl.9039 Garassino, 2022, 973MO KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, Ann. Oncol., 33, S992, 10.1016/j.annonc.2022.07.1101 5-year update from KEYNOTE-407: pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC) | OncologyPRO. Accessed January 5, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-congress/5-year-update-from-keynote-407-pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-nsclc. Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet Lond. Engl., 393, 1819, 10.1016/S0140-6736(18)32409-7 Castro, 2021, 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer, J. Immunother. Cancer, 9, A390, 10.1136/jitc-2021-SITC2021.363 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond. Engl., 387, 1540, 10.1016/S0140-6736(15)01281-7 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Barlesi, 2016, Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: checkMate 017 and CheckMate 057 2-y update, Ann. Oncol., 27, vi420, 10.1093/annonc/mdw383.15 Hellmann, 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer, N. Engl. J. Med., 381, 2020, 10.1056/NEJMoa1910231 Brahmer, 2022, Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): results from CheckMate 227, J. Clin. Oncol., 40, 10.1200/JCO.2022.40.17_suppl.LBA9025 Paz-Ares, 2021, First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial, Lancet Oncol., 22, 198, 10.1016/S1470-2045(20)30641-0 Paz-Ares, 2022, First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA, J. Clin. Oncol., 40, 10.1200/JCO.2022.40.17_suppl.LBA9026 JNCCN 360 - NSCLC - ASCO 2022: 3-year trial update on nivolumab plus ipilimumab and chemotherapy for metastatic NSCLC. Accessed November 3, 2022. https://jnccn360.org/nsclc/news/asco-2022-3-year-trial-update-on-nivolumab-plus-ipilimumab-and-chemotherapy-for-metastatic-nsclc/. Sezer, 2021, Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, Lancet Lond. Engl., 397, 592, 10.1016/S0140-6736(21)00228-2 Ozguroglu M., Kilickap S., Sezer A., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Ho G.F., Kulyab Y., Dvorkin M., Zyuhal K. , Scheusan R.I., Li S., Pouliot J., Seebach F., Lowy I., Gullo G., Rietschel P. ESMO 2022: three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial. Accessed November 3, 2022. https://clin.larvol.com/abstract-detail/ESMO%202022/58748759/254711. Gogishvili, 2022, Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial, Nat. Med., 28, 2374, 10.1038/s41591-022-01977-y Herbst, 2020, Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC, N. Engl. J. Med., 383, 1328, 10.1056/NEJMoa1917346 Jassem, 2021, Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1–selected NSCLC, J. Thorac. Oncol., 16, 1872, 10.1016/j.jtho.2021.06.019 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N. Engl. J. Med., 378, 2288, 10.1056/NEJMoa1716948 West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol., 20, 924, 10.1016/S1470-2045(19)30167-6 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N. Engl. J. Med., 377, 1919, 10.1056/NEJMoa1709937 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056/NEJMoa1809697 Spigel, 2022, Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, J. Clin. Oncol., 10.1200/JCO.21.01308 Johnson, 2022, Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study, J. Clin. Oncol. Vanmeerbeek, 2020, Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology, Oncoimmunology, 9, 10.1080/2162402X.2019.1703449 Zhou, 2016, The oncolytic peptide LTX-315 triggers immunogenic cell death, Cell Death. Dis., 7, e2134, 10.1038/cddis.2016.47 Fucikova, 2020, Detection of immunogenic cell death and its relevance for cancer therapy, Cell Death. Dis., 11, 1013, 10.1038/s41419-020-03221-2 Hayashi, 2020, Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death, Nat. Commun., 11, 6299, 10.1038/s41467-020-19970-9 Iwata, 2019, [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model, PLoS ONE, 14, 10.1371/journal.pone.0222280 Šmahel, 2017, PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression, Int. J. Mol. Sci., 18, E1331, 10.3390/ijms18061331 Page, 2019, Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer, Npj Breast Cancer, 5, 34, 10.1038/s41523-019-0130-x McKenzie, 2017, The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy, JNCI J. Natl. Cancer Inst, 110, 777, 10.1093/jnci/djx257 Stagg, 2011, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proc. Natl. Acad. Sci. U. S. A., 108, 7142, 10.1073/pnas.1016569108 Yamazaki, 2020, PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models, Oncoimmunology, 9, 10.1080/2162402X.2020.1721810 Bauzon, 2019, Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells, Oncoimmunology, 8, 10.1080/2162402X.2019.1565859 Han H.S., Diab S., Alemany C., et al. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer, Cancer Res (2020) 80 (4_Supplement), doi:10.1158/1538-7445.sabcs19-pd1-06. Cao A.T., Heiser R.A., Law C., Gardai S. Abstract 4914: Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses. Published online 2016. doi:10.1158/1538-7445.AM2016-4914. Kepp, 2019, Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade, Oncoimmunology, 8, 10.1080/2162402X.2019.1637188 Gerber, 2016, Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?, Biochem. Pharmacol., 102, 1, 10.1016/j.bcp.2015.12.008 Müller, 2015, Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade, Sci. Transl. Med., 7, 10.1126/scitranslmed.aac4925 Datopotamab Deruxtecan (Dato-DXd) and pembrolizumab with or without platinum chemotherapy in 1L non-small cell lung cancer (TROPION-Lung07) - full text view - ClinicalTrials.gov. Accessed January 6, 2023. https://clinicaltrials.gov/ct2/show/NCT05555732. Puzanov, 2017, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunother. Cancer, 5, 95, 10.1186/s40425-017-0300-z Man, 2018, Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis, Asia Pac. J. Clin. Oncol., 14, 141, 10.1111/ajco.12838 Masters, 2018, Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads, Invest. New Drugs, 36, 121, 10.1007/s10637-017-0520-6 Hamilton E., Shapiro C., Petrylak D. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Accessed October 8, 2022. https://www.abstractsonline.com/pp8/#!/9223/presentation/798. Drugs@FDA: fDA-Approved Drugs. Accessed November 5, 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Emens, 2020, Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, Lancet Oncol., 21, 1283, 10.1016/S1470-2045(20)30465-4 Waks, 2020, A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC), J. Clin. Oncol., 38, 1046, 10.1200/JCO.2020.38.15_suppl.1046 Drugs@FDA: fDA-approved drugs. Accessed October 11, 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann. Oncol., 30, 1321, 10.1093/annonc/mdz167 Calles, 2020, Checkpoint blockade in lung cancer with driver mutation: choose the road wisely, Am. Soc. Clin. Oncol. Educ. Book, 372, 10.1200/EDBK_280795